G1 Therapeutics Inc (GTHX) has released an update.
G1 Therapeutics, Inc. has announced that the ongoing Phase 3 clinical trial for its new treatment combining trilaciclib with established cancer drugs is set to continue to final analysis. This decision, backed by an independent committee, marks a significant step in the drug’s development for patients with an aggressive form of breast cancer, offering hope for improved treatment options in the future.
For further insights into GTHX stock, check out TipRanks’ Stock Analysis page.
